Search results
Results from the WOW.Com Content Network
With several key data updates expected in 2025, the stock appears well-positioned for long-term growth, the analyst adds. ... and a price target of $172. BioNTech’s oncology pipeline was ...
Monday’s market selloff skipped past BioNTech (BNTX). The German biotech ended the session posting a 12% gain after news that two of the COVID-19 vaccine candidates it is co-developing with ...
Price Action: BNTX stock is up 5.87% at $112.57 at the last check on Wednesday. Read Next: Regeneron/Sanofi’s Dupixent Approval Signals Major Treatment Breakthrough For Smokers’ Lung Disease
COST data by YCharts. 3. Value stocks increase in popularity. Many stocks now trade at premium prices thanks to the huge gains of the last couple of years. Sooner or later, though, investors will ...
BioNTech is scheduled to provide detailed full-year 2024 guidance alongside its 2023 financial results on March 20. ($1 = 0.9141 euros) (Editing by Rachel More and Matthias Williams)
BioNTech was founded in 2008 based on research by Uğur Şahin, Özlem Türeci, [8] and Christoph Huber, [9] with a seed investment of €180 million [10] from MIG Capital, a Munich-based venture capital firm, the family office of Andreas and Thomas Strüngmann, and the present chairman of the supervisory board, Helmut Jeggle.
Monday, BioNTech SE (NASDAQ:BNTX) reported a first-quarter EPS loss of 1.31 euros ($1.41 loss), a shift from an income of 2.05 euros, missing the consensus loss of 97 cents. The COVID-19 vaccine ...
Coronavirus is a global pandemic. With nearly 220,000 patients infected with COVID-19 at last report (according to Johns Hopkins University data), the populations of 158 countries affected, and ...